Despite being studied for decades, the chemotherapy drug cisplatin is revealing new aspects of how it works. Researchers at Winship Cancer Institute of Emory University have identified an enzyme responsible for making tumors and cancer cell lines resistant to cisplatin, along with an experimental drug that targets that enzyme.
The results were published on July 19 in Cancer Cell.
Sumin Kang, PhD, and colleagues at Winship decided to look for enzymes whose activity was necessary for cancer cells to withstand cisplatin treatment. Dr. Kang is a faculty member in the CB and MSP programs.
Click here to view the full story in Lab Land - The Emory Health Sciences Research Blog.